Revolutionizing Allergy Treatment: How NMN & NR Could Curb Anaphylaxis and Allergy Risks?
Anaphylaxis, a sudden, life-threatening allergic shock, can be triggered by allergenic foods, medicines, or chemicals. An estimated 1.6% to 5.1% of Americans have experienced this severe allergic reaction. Epinephrine shots remain the only known treatment, underscoring the pressing need for more effective interventions.
The Role of NMN and NR
Recent animal studies suggest nicotinamide, an NAD+ precursor, may inhibit the release of pro-inflammatory histamines from mast cells, offering a new strategy to counter these allergic reactions. Consequently, researchers are keen to explore the efficacy of potent NAD+ boosters, such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), in managing anaphylaxis.
Anaphylaxis and NAD+ Precursors
Research published in Theranostics by Park et al. from Chonbuk National University Medical School in Korea demonstrates that administering NMN or NR to mice could help stabilize body temperature during anaphylaxis. The study also revealed a significant reduction in the release of pro-inflammatory proteins from mast cells following treatment with NMN or NR. These findings suggest that NMN or NR supplementation could help reduce severe anaphylactic reactions by inhibiting mast cell release of pro-inflammatory proteins.
Mitigating Anaphylactic Responses
The research team tested NMN's effectiveness by administering a dose of 100 mg/kg to mice. Twenty-four hours later, the mice were exposed to anaphylaxis-inducing antigens. The team observed a reduced drop in body temperature and lessened ear swelling in NMN-treated mice. Similar outcomes were achieved with a 150 mg/kg dosage of NR, reinforcing the potential benefits of NAD+ precursor supplementation in mitigating anaphylactic reactions.
NMN, NR, and Mast Cell Response
By isolating mast cells from the bone marrow of healthy mice and exposing them to allergy-inducing antigens, the team found that NMN or NR treatment resulted in nearly a 50% reduction in the release of inflammatory proteins. This supports the role of NMN and NR in curbing the mast cell inflammatory response, which may in turn lessen the physiological effects of anaphylaxis.
Exploring the Impact of NAD+ Precursors on Routine Allergy Symptoms
The discovery that NMN and NR treatments can diminish the release of pro-inflammatory proteins like histamine and IL-6 from mast cells raises an important question: Can NAD+ precursors also alleviate symptoms of everyday allergies? While anaphylaxis represents the extreme end of allergic reactions, similar cellular mechanisms are at play in routine allergies, where the release of histamine and IL-6 is a common occurrence.
This leads to the possibility that NMN or NR supplementation might not only be beneficial in severe cases like anaphylaxis but also in managing milder, more common allergic reactions such as those to tree pollen. Future research, particularly human clinical trials, could focus on assessing the impact of these supplements on inflammatory markers in the blood and the severity of allergy symptoms in individuals with typical allergies.
Sirt6: A Vital Role in Anaphylaxis Mitigation
The protein Sirt6 plays a critical role in managing mast cells' response to allergens. The absence of Sirt6 negates the beneficial impact of NMN and NR against anaphylaxis, indicating that Sirt6 function is necessary to manage the anaphylactic response.
Conclusion
The intriguing research on NMN and NR as potential agents in alleviating severe allergic reactions like anaphylaxis opens new avenues in therapeutic development. This preliminary data, though requiring further validation in human trials, points to the exciting possibilities offered by NAD+ precursors.
HealthspanX Ultra Pure NMN™, in particular, may emerge as a valuable tool in enhancing cellular health and resilience, potentially offering a novel approach to managing allergies and supporting overall well-being.
Citations
Kim HW, Ryoo GH, Jang HY, et al. NAD+-boosting molecules suppress mast cell degranulation and anaphylactic responses in mice. Theranostics. 2022;12(7):3316-3328. Published 2022 Apr 11. doi:10.7150/thno.69684 10.7150/thno.69684. PMID: 35547746; PMCID: PMC9065190.